Berenberg reiterates Buy on AXA stock, EUR77 price target

Berenberg reiterated its Buy rating on AXA with a €77 price target, citing an 11.8x P/E and 0.31 PEG ratio alongside an assessment that the shares are undervalued. AXA raised its underlying EPS CAGR target to 7-9% for 2027-29 from 6-8% for 2024-26 and lifted its ROE target to 15-17%, having already delivered 17% ROE over the last 12 months through Q2 2026. The insurer aims to hold its combined ratio near 91% while improving retail retention by 70bps and SME/mid-market retention by 60bps, partly through AI-enabled distribution; however, Erste downgraded the shares to Hold amid AXA's transition following the sale of its asset-management unit to BNP Paribas.

Analysis

AXA’s valuation case hinges less on the upgraded long-term targets than on whether growth can be added without reopening the underwriting-margin trade-off. Improving retention is economically attractive because renewal premiums carry materially lower acquisition costs than new business, but a 60-70bp retention improvement could also signal looser pricing discipline if competitors respond. The key near-term KPI is gross written premium growth versus claims inflation and the combined ratio: stable reported profitability without reserve strengthening would support a rerating; any deterioration in attritional loss ratio would expose the guidance as aspirational.

The disposal of asset management increases the purity of the insurance earnings stream but removes fee-based diversification and makes AXA more sensitive to catastrophe losses, pricing cycles and European rates. BNP’s strategic benefit is not simply incremental AUM: distribution, financing and client-data synergies could improve the economics of the acquired platform, whereas AXA shareholders should demand evidence that released capital is returned or redeployed above the group’s cost of equity. This is a 6-18 month capital-allocation and execution debate, not a material days-to-weeks earnings catalyst.

Consensus may be underweight the possibility that AI-led distribution raises expense leverage rather than only retention, particularly in SME commercial lines where broker/service costs are high. Conversely, the market may be over-crediting the AI narrative before disclosure of conversion, churn, and expense-ratio outcomes. A sustained decline in European sovereign yields would be a separate headwind to investment income and could offset a meaningful portion of operating improvements over the next 12 months.

Key Decisions for Investors

• Maintain a selective long bias in AXA (CS:FP) only on confirmation that 2027 premium growth accelerates while the combined ratio remains at or below management’s normalized level; target a 6-12 month rerating toward European multiline-insurer peers. Thesis is falsified by adverse reserve development, a >100bp combined-ratio miss, or retention gains achieved through weaker pricing.
• Use a pair trade: long CS:FP / short Allianz (ALV:GR) or Zurich (ZURN:SW) in equal beta-adjusted amounts over 3-6 months if AXA begins reporting retention and expense-ratio progress. AXA offers greater operating-leverage upside from distribution modernization; exit if peer-relative underwriting margins narrow rather than converge upward.
• Do not chase BNP (BNP:FP) on the asset-management transaction alone. Set an alert for disclosed purchase economics, CET1 impact, cost-synergy timing and antitrust remedies; initiate only if pro-forma returns exceed BNP’s cost of equity without impairing capital return capacity.
• Monitor euro 10-year yields and European catastrophe-loss updates as hedge triggers. If yields fall sharply or major-loss assumptions rise, reduce insurance exposure regardless of top-line growth, as investment-income and claims pressure can overwhelm the retention thesis.